These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 1356788)

  • 1. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist.
    Mierau J; Schingnitz G
    Eur J Pharmacol; 1992 May; 215(2-3):161-70. PubMed ID: 1356788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The behavioural effects of pramipexole, a novel dopamine receptor agonist.
    Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
    Eur J Pharmacol; 1997 Apr; 324(1):31-7. PubMed ID: 9137910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pramipexole, a dopamine D2 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo.
    Carter AJ; Müller RE
    Eur J Pharmacol; 1991 Jul; 200(1):65-72. PubMed ID: 1685123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation by D2 dopamine receptors of in vivo dopamine synthesis in striata of rats and mice with experimental parkinsonism.
    Richard MG; Bennett JP
    Exp Neurol; 1994 Sep; 129(1):57-63. PubMed ID: 7925842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dopamine autoreceptor agonist B-HT 920 stimulates denervated postsynaptic brain dopamine receptors in rodent and primate models of Parkinson's disease: a novel approach to treatment.
    Hinzen D; Hornykiewicz O; Kobinger W; Pichler L; Pifl C; Schingnitz G
    Eur J Pharmacol; 1986 Nov; 131(1):75-86. PubMed ID: 3816949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the D3 preferring dopamine agonist pramipexole on sleep and waking, locomotor activity and striatal dopamine release in rats.
    Lagos P; Scorza C; Monti JM; Jantos H; Reyes-Parada M; Silveira R; Ponzoni A
    Eur Neuropsychopharmacol; 1998 May; 8(2):113-20. PubMed ID: 9619689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Talipexole or pramipexole combinations with chloro-APB (SKF 82958) in MPTP-induced hemiparkinsonian monkeys.
    Domino EF; Ni L; Zhang H; Kohno Y; Sasa M
    Eur J Pharmacol; 1997 May; 325(2-3):137-44. PubMed ID: 9163560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats.
    Lorenc-Koci E; Wolfarth S
    Eur J Pharmacol; 1999 Nov; 385(1):39-46. PubMed ID: 10594343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6N mice.
    Kitamura Y; Kohno Y; Nakazawa M; Nomura Y
    Jpn J Pharmacol; 1997 May; 74(1):51-7. PubMed ID: 9195297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Occurrence of yawning and decrease of prolactin levels via stimulation of dopamine D2-receptors after administration of SND 919 in rats.
    Matsumoto S; Yamada K; Nagashima M; Domae M; Shirakawa K; Furukawa T
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Jul; 340(1):21-5. PubMed ID: 2571944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.
    Kikuchi T; Tottori K; Uwahodo Y; Hirose T; Miwa T; Oshiro Y; Morita S
    J Pharmacol Exp Ther; 1995 Jul; 274(1):329-36. PubMed ID: 7616416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
    Sonsalla PK; Manzino L; Heikkila RE
    J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-methyl-D-aspartate receptor antagonist and dopamine D1 and D2 agonist interactions in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
    Domino EF; Sheng J
    J Pharmacol Exp Ther; 1993 Jan; 264(1):221-5. PubMed ID: 8093726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective unilateral inactivation of striatal D1 and D2 dopamine receptor subtypes by EEDQ: turning behavior elicited by D2 dopamine receptor agonists.
    Giorgi O; Biggio G
    Brain Res; 1990 Nov; 533(1):53-9. PubMed ID: 1982234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease.
    Belluzzi JD; Domino EF; May JM; Bankiewicz KS; McAfee DA
    Mov Disord; 1994 Mar; 9(2):147-54. PubMed ID: 7910948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
    Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D
    BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excitation of type II anterior caudate neurons by stimulation of dopamine D3 receptors.
    Piercey MF; Hyslop DK; Hoffmann WE
    Brain Res; 1997 Jul; 762(1-2):19-28. PubMed ID: 9262154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
    LaHoste GJ; Marshall JF
    Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
    Shiosaki K; Jenner P; Asin KE; Britton DR; Lin CW; Michaelides M; Smith L; Bianchi B; Didomenico S; Hodges L; Hong Y; Mahan L; Mikusa J; Miller T; Nikkel A; Stashko M; Witte D; Williams M
    J Pharmacol Exp Ther; 1996 Jan; 276(1):150-60. PubMed ID: 8558425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of several partial dopamine D2 receptor agonists in Cebus apella monkeys previously treated with haloperidol.
    Peacock L; Gerlach J
    Eur J Pharmacol; 1993 Jun; 237(2-3):329-40. PubMed ID: 8103465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.